期刊文献+

Posttransplantation lymphoproliferative disorder involving the central nervous system in liver transplant recipients

Posttransplantation lymphoproliferative disorder involving the central nervous system in liver transplant recipients
下载PDF
导出
摘要 BACKGROUND: Posttransplantation lymphoproliferative disorder (PTLD) involving the central nervous system (CNS) is a rare and serious complication associated with solid organ transplantation. We treated a case of PTLD with CNS involvement in a liver transplant recipient and reviewed the literature. METHOD: The clinicopathological features of a 53-year-old man were retrospectively analyzed. RESULTS: Metastasis of the hepatoma was preoperatively considered on the basis of clinical findings. Craniotomy was performed and PTLD was diagnosed pathologically. The patient was treated with antiviral agents, radiation therapy, and chemotherapy; the immunosuppressive medication was reduced. The patient is still alive after follow-up for 14 months. CONCLUSIONS: Definitive diagnosis of PTLD is only established on the basis of histopathologic evaluation of the tissue. Although there are several ways to manage PTLD with CNS involvement, the prognosis is still poor. BACKGROUND: Posttransplantation lymphoproliferative disorder (PTLD) involving the central nervous system (CNS) is a rare and serious complication associated with solid organ transplantation. We treated a case of PTLD with CNS involvement in a liver transplant recipient and reviewed the literature. METHOD: The clinicopathological features of a 53-year-old man were retrospectively analyzed. RESULTS: Metastasis of the hepatoma was preoperatively considered on the basis of clinical findings. Craniotomy was performed and PTLD was diagnosed pathologically. The patient was treated with antiviral agents, radiation therapy, and chemotherapy; the immunosuppressive medication was reduced. The patient is still alive after follow-up for 14 months. CONCLUSIONS: Definitive diagnosis of PTLD is only established on the basis of histopathologic evaluation of the tissue. Although there are several ways to manage PTLD with CNS involvement, the prognosis is still poor.
出处 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS 2008年第5期551-554,共4页 国际肝胆胰疾病杂志(英文版)
关键词 liver transplantation central nervous system IMMUNOSUPPRESSION posttransplant lymphoproliferative disorder liver transplantation central nervous system immunosuppression posttransplant lymphoproliferative disorder
  • 相关文献

参考文献13

  • 1Song-Feng Yu, Li-Hua Wu and Shu-Sen Zheng Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.Genetic factors for individual administration of immunosuppressants in organ transplantation[J].Hepatobiliary & Pancreatic Diseases International,2006,5(3):337-344. 被引量:4
  • 2Basgoz N,Preiksaitis JK.Post-transplant lymphoproliferativedisorder. Infectious Diseases in Clinical Practice . 1995
  • 3Donnelly LF,,Frush DP,Marshall KW,White KS.Lymphoproliferative disorders:CT findings inimmunocompromised children. American Journal of Roentgenology . 1998
  • 4Walker RC,Paya CV,Marshall WF,Strickler JG,WiesnerRH,Velosa JA,et al.Pretransplantation seronegativeEpstein-Barr virus status is the primary risk factor forposttransplantation lymphoproliferative disorder in adultheart,lung,and other solid organ transplantations. J HeartLung Transplant . 1995
  • 5Zangwill SD,Hsu DT,Kichuk MR,Garvin JH,StolarCJ,Haddad J Jr,et al.Incidence and outcome of primaryEpstein-Barr virus infection and lymphoproliferativedisease in pediatric heart transplant recipients. J HeartLung Transplant . 1998
  • 6VA Morrison,DL Dunn,JC Manivel,KJ Gajl-Peczalska,BA Peterson.Clinical characteristics of post-transplant lymphoproliferative disorders. The American Journal of Medicine . 1994
  • 7Murray,J. E.,Wilson,R. E.,Tilney,N. L.,Merrill,J. P.,Cooper,W. C.,Britch,A. G.,Carpenter,C. B.,Hager,E. B.,Dammin,G. J.,Harrison,J. H.Five years experience in renal transplantation with immunosuppressive drugs. Annals of Surgery . 1968
  • 8Buell JF,Gross TG,Hanaway MJ,et al.Posttransplantlymphoproliferative disorder:significance of central nervoussystem involvement. Transplantation Proceedings . 2005
  • 9Craig,F. E.,Gulley,M. L.,Banks,P. M.Post-transplantation lymphoproliferative disorders. American Journal of Clinical Pathology . 1993
  • 10Benkerrou,M,Durandy,AA,Fischer,A.Therapy for transplant related lymphoproliferative diseases. Hematology Oncology Clinics of North America . 1993

二级参考文献60

  • 1Kim RB;Leake BF;Choo EF.Identification of functionally variant MDR1 alleles among European Americans and African Americans,2001.
  • 2Wu J,Zheng SS.Liver transplantation in China: problems and their solutions. Journal of Hepatobiliary Pancreat Disease . 2004
  • 3Masahiro Hiratsuka,Yoh Takekuma,Naomi Endo,Kaori Narahara,Samar Hamdy,Yukinaga Kishikawa,Masaki Matsuura,Yasuyuki Agatsuma,Tomoko Inoue,Michinao Mizugaki.[J]. European Journal of Clinical Pharmacology . 2002 (6)
  • 4L. P. Rivory,H. Qin,S. J. Clarke,J. Eris,G. Duggin,E. Ray,R. J. Trent,J. F. Bishop.Frequency of cytochrome P 450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance[J]. European Journal of Clinical Pharmacology . 2000 (5)
  • 5Edgar A. Mueller,John M. Kovarik,Johannes B. van Bree,Wolfgang Tetzloff,Joachim Grevel,Klaus Kutz.Improved Dose Linearity of Cyclosporine Pharmacokinetics from a Microemulsion Formulation[J]. Pharmaceutical Research . 1994 (2)
  • 6Bradley JA,Gibbs P,Watson C.Update in transplantation--2003. Clinical Transplantation . 2003
  • 7Kalow W,Tang BK,Endrenyi L.Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics . 1998
  • 8Evans WE,Relling MV.Pharmacogenomics: translating functional genomics into rational therapeutics. Science . 1999
  • 9Hesselink DA,van Schaik RH,van der Heiden IP,van der Werf M,Gregoor PJ,Lindemans J, et al.Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clinical Pharmacology and Therapeutics . 2003
  • 10Anglicheau D,Verstuyft C,Laurent-Puig P,Becquemont L,Schlageter MH,Cassinat B, et al.Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. Journal of the American Society of Nephrology . 2003

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部